Clinical Trial Update: Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Relatrilfa-α in combination with single-agent chemotherapy as neoadjuvant therapy for resectable stage II-III non-small cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Relatrilfa-α

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: NSCLC | Phase 2 | Status: NOT_YET_RECRUITING